Michel Carles

Michel Carles

Auto-generated profile, based on publicly available information

Michel Carles

CHU Pointe-à-Pitre

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DRDaniel Re
Daniel Re
BSBarbara Seitz-Polski
Barbara Seitz-Polski
VBVesna Brglez
Vesna Brglez
MCMichel Carles
Michel Carles
DGDaisy Graça
Daisy Graça
JBJérôme Barrière
Jérôme Barrière
Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.

8 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
JCJohan Courjon
Johan Courjon
ODOcéane Dufies
Océane Dufies
ARAlexandre Robert
Alexandre Robert
LBLaurent Bailly
Laurent Bailly
CTCédric Torre
Cédric Torre
Laurent BoyerLaurent Boyer
Laurent Boyer
Dysregulated immune response is the key factor leading to unfavorable coronavirus disease 2019 (COVID-19) outcome. Depending on the pathogen-associated molecular pattern, the NLRP3 inflammasome can play a crucial role during innate immunity activation. To date, studies describing the NLRP3 response during severe acute respiratory syndrome coronavirus 2 infection in patients are lacking. We prospectively monitored caspase-1 activation levels in peripheral myeloid cells from healthy donors and patients with mild to critical COVID-19. The caspase-1 activation potential in response to NLRP3 inflammasome stimulation was opposed between nonclassical monocytes and CD66b+CD16dim granulocytes in severe and critical COVID-19 patients. Unexpectedly, the CD66b+CD16dim granulocytes had decreased nigericin-triggered caspase-1 activation potential associated with an increased percentage of NLRP3 inflammasome impaired immature neutrophils and a loss of eosinophils in the blood. In patients who recovered from COVID-19, nigericin-triggered caspase-1 activation potential in CD66b+CD16dim cells was restored and the proportion of immature neutrophils was similar to control. Here, we reveal that NLRP3 inflammasome activation potential differs among myeloid cells and could be used as a biomarker of a COVID-19 patient’s evolution. This assay could be a useful tool to predict patient outcome. This trial was registered at www.clinicaltrials.gov as #NCT04385017.

16 December 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
JBJérôme Barrière
Jérôme Barrière
MCMichel Carles
Michel Carles
CAClarisse Audigier-Valette
Clarisse Audigier-Valette
DRDaniel Re
Daniel Re
ZAZoubir Adjtoutah
Zoubir Adjtoutah
GZGérard Zalcman
Gérard Zalcman

1 November 2016 in The Lancet
Verified
Journal Article
Closed access
MCMichel Carles
Michel Carles
JLJacques Levraut
Jacques Levraut
JGJean François Gonzalez
Jean François Gonzalez
FVFrançois Valli
François Valli
LBLoic Bornard
Loic Bornard

1 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
JBJérôme Barrière
Jérôme Barrière
DRDaniel Re
Daniel Re
FPFrédéric Peyrade
Frédéric Peyrade
MCMichel Carles
Michel Carles

20 November 2007 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
PDF file
MCM. Carles
M. Carles
JDJ. Dellamonica
J. Dellamonica
JRJ. Roux
J. Roux
DLD. Lena
D. Lena
JLJ. Levraut
J. Levraut
MRM. Raucoules-Aime
M. Raucoules-Aime
Ischaemia/reperfusion (I/R) is one of the main pathophysiological phenomena involved in the anaesthetic practice. The authors hypothesized that anaesthetic regimens can influence skeletal muscle tolerance to tourniquet-induced I/R that should be reflected by the interstitial metabolite levels of anaerobic glycolysis. Microdialysis probes were implanted in three groups of 10 patients each receiving either sevoflurane (SEVO), propofol (PRO), or spinal (SA) anaesthesia (for induction and maintenance). SA group was considered as a control group. Interstitial fluid was obtained during tourniquet-induced I/R and was analysed for interstitial glucose, lactate, pyruvate, and glycerol. The microdialysis flow rate was 0.5 µl min−1. Compared with the control group, the SEVO group had a higher level of both lactate and pyruvate and an increase in glucose during ischaemia. In contrast, the PRO group had a lower level of pyruvate, resulting in a significant higher increase (eight times from baseline) of the lactate pyruvate ratio. Glucose level remained low in this group. During reperfusion, lactate, pyruvate, and glucose remained at a significantly higher level in the SEVO group. In the PRO group, there was no difference in lactate, pyruvate, and glucose levels compared with the control group. The interstitial level of glycerol exhibits only few and comparable changes during I/R between the groups. Our results indicate that there is a better availability of interstitial glycolysis metabolites (glucose, lactate, and pyruvate) in the skeletal muscle during ischaemia and reperfusion after sevoflurane exposure than after propofol, suggesting a potential preconditioning effect of sevoflurane on tourniquet-induced skeletal muscle I/R.